Go Pro
NASDAQ:PGEN

Precigen Q2 2025 Earnings Report

Precigen logo
$7.44 -0.45 (-5.70%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$7.46 +0.02 (+0.28%)
As of 04:35 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Precigen EPS Results

Actual EPS
-$0.11
Consensus EPS
-$0.14
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

Precigen Revenue Results

Actual Revenue
$0.86 million
Expected Revenue
$0.67 million
Beat/Miss
Beat by +$193.00 thousand
YoY Revenue Growth
N/A

Precigen Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 12, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Precigen's Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Precigen Earnings Headlines

Precigen (NASDAQ:PGEN) Hits New 12-Month High - What's Next?
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.tc pixel
Precigen's AdenoVerse Receives FDA Platform Technology Designation
See More Precigen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Precigen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Precigen and other key companies, straight to your email.

About Precigen

Precigen (NASDAQ:PGEN) (NASDAQ:PGEN) is a biotechnology company focused on developing gene and cell therapies for cancer and other serious diseases. The company uses its synthetic biology platforms to engineer targeted medicines designed to improve treatment effectiveness, durability and safety.

Precigen’s technology portfolio includes its UltraCAR-T platform for developing next-generation CAR-T cell therapies, the AdenoVerse platform for gene delivery and immunotherapy applications, and ActoBiotics technology for the localized delivery of therapeutic proteins. Its pipeline has included programs in oncology, autoimmune disease and infectious disease.

One of the company’s leading programs is PRGN-2012, an investigational immunotherapy developed for recurrent respiratory papillomatosis, a rare disease caused by human papillomavirus. Precigen conducts research and clinical development through collaborations and operations serving patients and healthcare markets in the United States and internationally.

View Precigen Profile